Dapagliflozin improved symptoms and physical limitations in patients with heart failure (HF) with preserved ejection fraction, according to results from the PRESERVED-HF trial.
Dapagliflozin eases symptoms and physical limitations among patients who have heart failure with preserved ejection fraction (HFpEF) within a relatively short time period.
Treatment with dapagliflozin improves the symptoms of patients with heart failure with preserved ejection fraction (HFpEF), according to new findings presented at the Heart Failure Society of America's Annual Scientific Meeting.
This week we are talking with Dr. Elizabeth Cathcart-Rake, medical breast oncologist at Saint Luke’s Cancer Institute about preventive screenings, why early detection is key, and risk factors that women should keep in mind for breast cancer.
The SGLT2 inhibitor dapagliflozin scored a clear win in a randomized, controlled trial with more than 300 U.S. patients with heart failure with preserved ejection fraction (HFpEF).
Dr. Andrew Schlachter, pulmonologist and critical care physician at Saint Luke's, talks to FOX4 about Duvernay-Tardif returning to play with the Chiefs this season.
We’re talking about COVID-19 boosters and flu shots, the upcoming influenza season, and how the community can help health care workers in the months ahead.
Saint Luke’s Health System Critical Access Region Chief Executive Officer Steve Schieber answered questions during a conference call on September 1st regarding the COVID-19 vaccination mandate announced by Saint Luke’s.
